| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
|
JAMA
|
2008
|
13.35
|
|
2
|
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
|
JAMA
|
2011
|
11.02
|
|
3
|
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
|
J Clin Oncol
|
2008
|
6.11
|
|
4
|
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
|
Lancet
|
2011
|
5.21
|
|
5
|
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
|
J Clin Oncol
|
2007
|
3.79
|
|
6
|
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
|
J Clin Oncol
|
2009
|
3.72
|
|
7
|
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
|
J Clin Oncol
|
2011
|
2.46
|
|
8
|
Cutaneous angiosarcoma of the scalp: a multidisciplinary approach.
|
Cancer
|
2003
|
2.23
|
|
9
|
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.
|
J Clin Oncol
|
2011
|
2.21
|
|
10
|
Chordoma: the nonsarcoma primary bone tumor.
|
Oncologist
|
2007
|
2.10
|
|
11
|
Soft tissue sarcomas of adults: state of the translational science.
|
Clin Cancer Res
|
2003
|
1.81
|
|
12
|
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
|
J Clin Oncol
|
2004
|
1.69
|
|
13
|
Medical and pediatric oncology, not adult and pediatric oncology.
|
J Clin Oncol
|
2005
|
1.66
|
|
14
|
Pulmonary nodule volumetric measurement variability as a function of CT slice thickness and nodule morphology.
|
AJR Am J Roentgenol
|
2007
|
1.65
|
|
15
|
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.
|
J Clin Oncol
|
2009
|
1.38
|
|
16
|
Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma.
|
Cancer Res
|
2004
|
1.35
|
|
17
|
Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors.
|
Oncologist
|
2008
|
1.34
|
|
18
|
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
|
Cancer
|
2013
|
1.32
|
|
19
|
Selection of response criteria for clinical trials of sarcoma treatment.
|
Oncologist
|
2008
|
1.30
|
|
20
|
Cancer survivors in the United States: a review of the literature and a call to action.
|
Int J Med Sci
|
2012
|
1.30
|
|
21
|
Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.
|
Breast Cancer Res Treat
|
2005
|
1.30
|
|
22
|
When progressive disease does not mean treatment failure: reconsidering the criteria for progression.
|
J Natl Cancer Inst
|
2012
|
1.28
|
|
23
|
Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.
|
Clin Cancer Res
|
2010
|
1.23
|
|
24
|
Prioritization in comparative effectiveness research: the CANCERGEN Experience.
|
Med Care
|
2012
|
1.17
|
|
25
|
Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701).
|
Cancer Causes Control
|
2012
|
1.15
|
|
26
|
The development and testing of a measure assessing clinician beliefs about patient self-management.
|
Health Expect
|
2009
|
1.12
|
|
27
|
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
|
Stat Med
|
2003
|
1.12
|
|
28
|
How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment.
|
Health Aff (Millwood)
|
2011
|
1.11
|
|
29
|
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.
|
JAMA
|
2013
|
1.07
|
|
30
|
Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.07
|
|
31
|
Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition.
|
Pediatr Blood Cancer
|
2006
|
1.04
|
|
32
|
Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma.
|
Eur J Cancer
|
2012
|
1.02
|
|
33
|
Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.
|
J Clin Oncol
|
2005
|
0.98
|
|
34
|
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
|
J Clin Oncol
|
2005
|
0.97
|
|
35
|
Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines.
|
Cancer
|
2007
|
0.96
|
|
36
|
Gardner's syndrome in a 40-year-old woman: successful treatment of locally aggressive desmoid tumors with cytotoxic chemotherapy.
|
World J Surg Oncol
|
2006
|
0.95
|
|
37
|
Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations.
|
Eur J Cancer
|
2010
|
0.93
|
|
38
|
Moving a randomized clinical trial into an observational cohort.
|
Clin Trials
|
2012
|
0.93
|
|
39
|
Small round cell sarcomas.
|
Semin Oncol
|
2009
|
0.92
|
|
40
|
Soft tissue sarcoma.
|
J Natl Compr Canc Netw
|
2007
|
0.91
|
|
41
|
Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons.
|
Cancer
|
2006
|
0.90
|
|
42
|
Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma.
|
J Clin Oncol
|
2003
|
0.90
|
|
43
|
Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.
|
Clin Cancer Res
|
2013
|
0.86
|
|
44
|
Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008.
|
Clin Cancer Res
|
2009
|
0.86
|
|
45
|
Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation.
|
Oncologist
|
2008
|
0.86
|
|
46
|
Metastatic dedifferentiated chordoma with elevated beta-hCG: a case report.
|
Am J Clin Oncol
|
2002
|
0.85
|
|
47
|
Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process.
|
J Comp Eff Res
|
2012
|
0.84
|
|
48
|
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
|
Cancer
|
2007
|
0.84
|
|
49
|
Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.
|
Mol Cancer Ther
|
2013
|
0.83
|
|
50
|
Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme.
|
Cancer Chemother Pharmacol
|
2005
|
0.81
|
|
51
|
Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma.
|
Am J Clin Oncol
|
2013
|
0.79
|
|
52
|
Myxoid malignant fibrous histiocytoma with multiple primary sites.
|
Sarcoma
|
2002
|
0.79
|
|
53
|
Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.
|
Cancer
|
2008
|
0.78
|
|
54
|
High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
|
Cancer
|
2003
|
0.77
|
|
55
|
Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
|
Clin Cancer Res
|
2003
|
0.77
|
|
56
|
Soft tissue sarcoma clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2005
|
0.76
|
|
57
|
Response to "A Porsche for patient accrual," by David Steinberg, Cancer Investigation, 2005, 23(8), pp. 741-743.
|
Cancer Invest
|
2006
|
0.75
|
|
58
|
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors.
|
Invest New Drugs
|
2010
|
0.75
|
|
59
|
Bone cancer clinical practice guidelines.
|
J Natl Compr Canc Netw
|
2005
|
0.75
|
|
60
|
Generic sirolimus: a future opportunity to decrease the cost of oncology care?
|
Clin Adv Hematol Oncol
|
2013
|
0.75
|
|
61
|
SWOG Cooperative Group biorepository resource: access for scientific research studies.
|
Clin Cancer Res
|
2011
|
0.75
|
|
62
|
Pharmacotherapy of sarcoma.
|
Expert Opin Pharmacother
|
2009
|
0.75
|